Braftovi, Erbitux, and mFOLFOX6 improved ORR to 60.9% in BRAF V600E-mutated mCRC compared to 40% with mFOLFOX6 alone. The FDA granted accelerated approval for the combination therapy in December 2024, ...

Of patients on Braftovi plus cetuximab and mFOLFOX6, 22.4% (n=15) had a response lasting 12 months or longer, compared to 11.4% (n=5) with chemotherapy with or without bevacizumab.

The drug cocktail includes Braftovi, Eli Lilly’s Erbitux and the chemo regimen mFOLFOX6. In patients with metastatic colorectal cancer harboring a BRAF V600E mutation, the combo not only staved ...

Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi ...

The estimated median duration of response was 13.9 months with Braftovi plus cetuximab and mFOLFOX6 and 11.1 months with chemotherapy with or without bevacizumab. Of patients on Braftovi plus ...

At the time of the ORR analysis, the safety profile of BRAFTOVI in combination with cetuximab and mFOLFOX6 continued to be consistent with the known safety profile of each respective agent.

On Saturday, Pfizer Inc. (NYSE:PFE) revealed results from the Phase 3 BREAKWATER trial evaluating Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and mFOLFOX6 (fluorouracil, ...

The estimated median duration of response as assessed by BICR was 13.9 months (95% Confidence Interval [CI]: 8.5-not estimable [NE]) with BRAFTOVI plus cetuximab and mFOLFOX6 and 11.1 months (95% CI: ...

Pfizer Inc. announced positive results from the phase 3 BREAKWATER trial evaluating Braftovi (encorafenib) in combination with cetuximab (marketed as Erbitux) and mFOLFOX6 (fluorouracil, leucovorin, ...